Ada göre bir ilaç arayın

Gengraf Capsules ve Böbrek yetmezliği

Gengraf Capsules ilacının Böbrek yetmezliği hastalığı ile etkileşiminin güvenlik kontrolünün sonucu.

Kontrolün sonucu:

Gengraf Capsules <> Böbrek yetmezliği

Güncellik: 23.07.2019 Eleştirmen: MD PHD P.M. Shkutko, in

Drugs.com, Rxlist.com, Webmd.com, Medscape.com gibi yetkili kaynaklara dayalı kontrolün sonucunda bu ilacın bu komorbid hastalık ile etkileşmesi halinde zarar verebilen veya olumsuz etkisini artırabilen kontrendikasyonlar veya yan etkiler bulundu.

Tüketici:

Siklosporin kullanımı romatoid artrit ya da anormal böbrek fonksiyonu ile sedef hastalığı olan hastalarda kullanılmamalıdır. Siklosporin artmış serum kreatinin ve kan üre nitrojen sonucu renal kan akımı geri dönüşümlü bir azalma ve glomerüler filtrasyon hızı neden olur. Hafif toksisite genellikle siklosporin doz azaltma yanıt verir. Kalıcı, kronik ve ilerleyici toksisite oluştu. Bu hastalarda böbrek biyopsisi interstisyel fibrozis, tübüler atrofi, global veya segmental glomeruloskleroz göstermek, damar veya kas hasarı pürüzsüz olabilir. Büyük toplu doz veya yüksek siklosporin düzeyleri yalak interstisyel fibrozis gelişimi ile ilişkili olabilir. Böbrek fonksiyonlarının klinik izleme gereklidir ve böbrek yetmezliği olan siklosporin kaynaklı toksisite, homogreft ret ayrımını, ve diğer nedenler önce doz ayarlamaları siklosporin tespit edilmelidir.

Kaynaklar

Bach JF, Feutren G, Noel LH, et al "Factors predictive of cyclosporine-induced nephrotoxicity: the role of cyclosporine blood levels." Transplant Proc 22 (1990): 1296-8
Frey FJ "Pharmacokinetic determinants of cyclosporine and prednisone in renal transplant patients." Kidney Int 39 (1991): 1034-50
Ballardie FW, Edwards BD, Hows J, et al "Disturbance in renal haemodynamics and physiology in bone marrow transplant recipients treated with ciclosporin A." Nephron 60 (1992): 17-24
Ludwin D, Bennett KJ, Grace EM, et al "Nephrotoxicity in patients with rheumatoid arthritis treated with cyclosporine." Transplant Proc 20 (1988): 367-70
Follath F, Wenk M, Vozeh S, et al "Intravenous cyclosporine kinetics in renal failure." Clin Pharmacol Ther 34 (1983): 638-43
Venkataramanan R, Ptachcinski RJ, Burckart GJ, et al "The clearance of cyclosporine by hemodialysis." J Clin Pharmacol 24 (1984): 528-31
"Product Information. Neoral Oral Solution (cyclosporine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Morales JM, Andres A, Hernandez E, et al "Fractional excretion of sodium is an early predictor of cyclosporine nephrotoxicity after renal transplantation." Transplant Proc 22 (1990): 1728-9
Forre O, Bjerkhoel F, Kjeldsenkragh J, Ostensen H, Astor T, Boe E, Lekven C, Sorensen JU, Karoliussen O, Dehli O, Glennas A, Kv "Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine - results of a 48-week multicenter study comparing low-dose cyclosporine with placebo." Arthritis Rheum 37 (1994): 1506-12
Dische FE, Neuberger J, Keating J, et al "Kidney pathology in liver allograft recipients after long-term treatment with cyclosporin A." Lab Invest 58 (1988): 395-402
Zachariae H, Hansen HE, Kragballe K, Olsen S "Morphologic renal changes during cyclosporine treatment of psoriasis." J Am Acad Dermatol 26 (1992): 415-9
Dijkmans BA, van Rijthoven AW, The HS, et al "Effect of cyclosporin on serum creatinine in patients with rheumatoid arthritis." Eur J Clin Pharmacol 31 (1987): 541-5
Bensen W, Tugwell P, Roberts RM, Ludwin D, Ross H, Grace E, Gent M "Combination therapy of cyclosporine with methotrexate and gold in rheumatoid arthritis (2 pilot studies)." J Rheumatol 21 (1994): 2034-8
Vernillet L, Moulin B, Dadoun C, et al "Pharmacokinetics of cyclosporine A in patients with nephrotic syndrome." Transplant Proc 20 (1988): 529-35
"Product Information. Sandimmune (cyclosporine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Boers M, van Rijthoven AW, The HS, et al "Serum creatinine levels two years later: follow-up of a placebo-controlled trial of cyclosporine in rheumatoid patients." Transplant Proc 20 (1988): 371-5
Harris KP, Jenkins D, Walls J "Nonsteroidal antiinflammatory drugs and cyclosporine: a potentially serious adverse interaction." Transplantation 46 (1988): 598-9
Bertani T, Ferrazzi P, Schieppati A, et al "Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients." Kidney Int 40 (1991): 243-50
Landewe RBM, The HSG, Vanrijthoven AWAM, Rietveld JR, Breedveld FC, Dijkmans BAC "Cyclosporine in common clinical practice: an estimation of the benefit/risk ratio in patients with rheumatoid arthritis." J Rheumatol 21 (1994): 1631-6
Albrecht K, Niebel W, Marggraf G, Eigler FW "Cyclosporine pharmacokinetics in the early course of renal transplantation." Transplant Proc 19 (1987): 17-9
Ptachcinski RJ, Venkataramanan R, Rosenthal JT, Burckart GJ, Taylor RJ, Hakala TR "Cyclosporine kinetics in renal transplantation." Clin Pharmacol Ther 38 (1985): 296-300
Margolis DJ, Guzzo C, Johnson J, Lazarus GS "Alterations in renal function in psoriasis patients treated with cyclosporine, 5 mg/kg/day." J Am Acad Dermatol 26 (1992): 195-7
Butkus DE, Herrera GA, Raju SS "Successful renal transplantation after cyclosporine-associated hemolytic-uremic syndrome following bilateral lung transplantation." Transplantation 54 (1992): 159-62
Cantarell MC, Capdevila L, Morlans M, Piera L "Uric acid calculus in renal transplant patients treated with cyclosporine." Clin Nephrol 35 (1991): 288
Messana JM, Rocher LL, Ellis CN, et al "Effects of cyclosporine on renal function in psoriasis patients." J Am Acad Dermatol 23 (1990): 1288-93
Neumayer HH, Budde K, Farber L, Haller P, Kohnen R, Maibucher A, Schuster A, Vollmar J, Waiser J, Luft FC "Conversion to microemulsion cyclosporine in stable renal transplant patients: results after one year." Clin Nephrol 45 (1996): 326-31
Burack DA, Griffith BP, Thompson ME, Kahl LE "Hyperuricemia and gout among heart transplant recipients receiving cyclosporine." Am J Med 92 (1992): 141-6
Awni WM, Kasiske BL, Heim-Duthoy K, Rao KV "Long-term cyclosporine pharmacokinetic changes in renal transplant recipients: effects of binding and metabolism." Clin Pharmacol Ther 45 (1989): 41-8
Madhok R, Torley HI, Capell HA "A study of the longterm efficacy and toxicity of cyclosporine A in rheumatoid arthritis." J Rheumatol 18 (1991): 1485-9